JohnCarlHornbergerMDMS

PubMed

• 3535 citations
  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a sy...
  Theo Vos, Ryan M Barber, Brad Bell, Amelia Bertozzi-Villa, Stan Biryukov
  Lancet. 2015-08-22
• 265 citations
  Recognition, diagnosis, and treatment of primary focal hyperhidrosis
  John Hornberger, Kevin Grimes, Markus Naumann, Dee Anna Glaser, Nicholas J. Lowe
  Journal of the American Academy of Dermatology. 2004-08-01
• 19 citations
  Cost-effectiveness of peginterferon alfa-2a (40 kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection
  John Hornberger, Francesca J. Torriani, Douglas T. Dieterich, Norbert Bräu, Mark S. Sulkowski
  Journal of Clinical Virology. 2006-08-01

Journal Articles

• Economic Analysis of a Noninvasive Molecular Pathologic Assay for Pigmented Skin Lesions  
  John Hornberger, MD, JAMA
• Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group  
  Badani K, Thompson DJS, Buerki C, Davicioni E, Garrison J, Ghadessi M, Mitra MP, Wood PJ, Hornberger J, Oncotarget, 1/1/2013
• Cost-benefit of 21-gene Breast Cancer Recurrence Score for Patients in Singapore  
  de Lima Lopes G, Chien R, Hornberger J, Breast J, 1/1/2013
• Comparative effectiveness in personalized medicine - clearly defining the intended use population  
  Hornberger J, Value Health, 1/1/2013
• Serum-based proteomic mass spectrometry test impacts clinical treatment decisions for patients with advanced non-small cell lung cancer  
  Ackerly WL, Nelson RE, Cowie RH, Spinella DG, Hornberger J, Curr Med Research Opinion, 1/1/2013
• Assigning value to medical algorithms - implications for personalized medicine  
  Hornberger J, Personalized Medicine, 1/1/2013
• Editorial to Computer modeling of diabetes and its complications: A report on the Fifth Mount Hood Challenge Meeting  
  Hornberger J, Value Health, 1/1/2013
• Is personalized medicine cost-effective?  
  Hornberger J, Amer Health Drug Benefits, 1/1/2013
• Response to Lamy et al Role of serine protease urokinase-type Plasminogen Activator (uPA) and Plasminogen Activator Inhibitor (PAI) type-1 as biomarkers in early stage...  
  Hornberger J, Gradishar WJ, Alvarado M, Chien R, Yu T, Gutierrez H, J Natl Cancer Inst, 1/1/2012
• Financial Implications of Choice of Dialysis Type of the Revised Medicare Payment System: An Economic Analysis  
  Hornberger J, Hirth R, Am J Kidney Diseases, 1/1/2012
• Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphocytic leukemia after responding to first-line rituximab plus chemo...  
  Hornberger J, Chien R, Friedmann M, Han L, Shewade A, Satram-Hoang S, Reyes C, Leuk Lymphoma, 1/1/2012
• Challenges in the development and reimbursement of personalized medicine–payer and manufacturer perspectives and implications for health economics and outcomes researc...  
  Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf A, Hornberger J, Hughes D, Li T, Malone D, Payne K, Siebert U, Towse A, Veenstra D, Watkins J, Value Health, 1/1/2012
• A multi-gene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs  
  Hornberger J, Lyman G, Chien R, Meropol N, Value Health, 1/1/2012
• Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and su...  
  Nystrom J, Hornberger J, Varadhachary G, Hornberger R, Gutierrez H, Henner W, Becker S, Amin M, Walker M, Oncotarget, 1/1/2012
• US Insurance Program’s Experience with a Multigene Assay for Early-Stage Breast Cancer  
  Hornberger J, Chien R, Krebs K, Hochheiser L, J Oncol Pract; Am J Manag Care, 1/1/2011
• Economic implications of 21-gene recurrence score assay: US multicenter experience  
  Hornberger J, Lyman GH, Chien R, J Clin Oncol, 1/1/2010
• Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy  
  Hornberger J, Simpson K, Shewade A, Dietz B, Baran R, Podsadecki T, Adv Ther, 1/1/2010
• Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli managed healthcare organization  
  Klang S, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J, Value Health, 1/1/2010
• Cost consequences of HIV-associated lipoatrophy  
  Hornberger J, Rajagopalan R, Shewade A, Loutfy MR, AIDS Care, 1/1/2009
• Review of “Electronic Health Records Guidelines for Clinicians and Administrators”  
  Hornberger J, JAMA, 1/1/2009
• Obstacles and proposed solutions to effective antiretroviral therapy in resource-limited settings  
  Bartlett J, Hornberger J, Shewade A, Bhor M, Rajagopalan R, JIAPAC, 1/1/2009
• Rechargeable Spinal Cord Stimulation System versus Nonrechargeable System for Patients with Failed Back Surgery Syndrome: A Cost-Consequences Analysis  
  Hornberger J, Hernandez J, Clark MA, et al, Clin J Pain, 1/1/2008
• Economic Evaluation of Rituximab plus cyclophosphamide, vincristine and prednisolone (CVP) for Advanced Follicular Lymphoma  
  Hornberger J, Reyes C, Valente N, et al, Leuk Lymph, 1/1/2008
• Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-Naïve, HIV-1 infected US veterans: 1992-2004  
  Holodniy M, Hornberger J, Rapoport D. et al, JAIDS, 1/1/2007
• Cost-effectiveness of a vaccine to prevent herpes zoster in older adults  
  Hornberger J, Robertus K, Ann Intern Med, 1/1/2006
• Join now to see all

Books/Book Chapters

• Klinische Nephrologie. 
  Chapter: Economic Considerations of the Hemodialysis Prescription. 
  Hornberger JEditors: HE Franz.Verlag, Landsberg1995
• Renal Physicians Association's Report 
  Chapter: Clinical Practice Guidelines on Adequacy of Hemodialysis 
  Hornberger J (Co-author)1993
• Japan's Health System. Efficiency and Effectiveness in Universal Care 
  Chapter: Chapter 14. Renal dialysis in Japan. 
  Hornberger J, Yoshikawa A, Holt MFaulkner & Gray, Washington,DC1993
• Proceedings of the Fifteenth Annual Symposium on Computer Applications in Medical Care 
  Chapter: Computer-assisted quality of life assessment for clinical trials. 
  Lenert LA, Hornberger JEditors: Kingsland LC.IEEE Computer Society, Washington, DC1991
• Join now to see all

Abstracts/Posters

• How are coverage decisions made in publicly-funded healthcare programs in low- and middle-income countries?
  Hornberger J, Shewade A, Gutierrez H, International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th Annual International Meeting, Baltimore, MD, 1/1/2011
• Economic impact of rituximab as maintenance therapy in previously untreated follicular non-Hodgkin lymphoma.
  Hornberger J, Friedmann M, Han L, Chien R, Hornberger R, Satram-Hoang S, Reyes C, CAJ Clin Oncol, 1/1/2011
• Cost-effectiveness of febuxostat in managing hyperuricemia in gout patients in Canada.
  Redding L, Hornberger J, Cowen JW, Chien R, Wang M, Annual Conference of Canadian Association of Population Therapeutics, Ottawa, Canada, 1/1/2011
• Meta-analysis of the decision impact of the 21-gene breast cancer Recurrence Score in clinical practice.
  Hornberger J, Chien R, 12th St. Gallen International Breast Cancer Conference, St. Gallen, Switzerland, 1/1/2011
• Cost-effectiveness of Oncotype DX breast cancer assay in Singapore.
  De Lima Lopes G, Chien R, Hornberger J, 12th St. Gallen International Breast Cancer Conference, St. Gallen, Switzerland, 1/1/2011
• Cost-effectiveness of febuxostat in managing hyperuricemia in gout patients in Canada.
  Redding L, Hornberger J, Cowen JW, Chien R, Wang M, CADTH Symposium, Vancouver, Canada, 1/1/2011
• Use of a multigene prognostic assay for selection of adjuvant chemotherapy in patients with stage II colon cancer: impact on quality-adjusted life expectancy and costs.
  Meropol N, Lyman G, Chien R, Hornberger J, Gastrointestinal Cancer Symposium, American Society of Clinical Oncology., San Francisco, CA, 1/1/2011
• Economics of a multigene assay to predict recurrence for early-stage breast cancer.
  Hornberger J, Chien R, Krebs K and Hochheiser, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, Baltimore, MD, 1/1/2010
• Meta-analysis of the decision impact of the 21-gene breast cancer Recurrence Score in clinical practice.
  Hornberger J , Chien R, 34th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 1/1/2010
• Economic evaluation of Oncotype DX® to target chemotherapy use in lymph-node negative, oestrogen positive, early-stage breast cancer in Ireland.
  Lacey L and Hornberger J, 13th Annual European Congress, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Prague, Czech Republic, 1/1/2010
• Cost-benefit of Oncotype DX breast cancer assay in Singapore.
  De Lima Lopes G, Chien R, Hornberger J, 4th Annual Asian-Pacific Congress, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Phuket, Thailand, 1/1/2010
• An open-source, interactive model to assess the outcomes and economics of diabetes interventions.
  Hornberger J, Shewade A, Rickert J, Hammer M, Groleau D, Adams J, Annual Conference of the Canadian Association for Population Therapeutics (CAPT), Toronto, Canada, 1/1/2010
• An open-source, interactive model to assess the outcomes and economics of diabetes interventions in Canada.
  Hornberger J, Shewade A, Rickert J, Hammer M, Groleau D, Adams J, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, Atlanta, GA, 1/1/2010
• Cost-effectiveness of rituximab, fludarabine, and cyclophosphamide (R-FC) in patients with previously untreated chronic lymphocytic leukemia (CLL).
  Hornberger J, Reyes C, Shewade A, Friedmann M, Chan L, Gutierrez H, Satram-Hoang S, Lerner S, Keating M, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, 1/1/2010
• LDT-SynFrame: An approach for assessing laboratory developed tests synthesized from prior appraisal frameworks, Genetic Testing and Molecular Biomarkers.
  Hornberger J, Chien R, Doberne J, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, Baltimore, MD, 1/1/2010
• The cost-effectiveness of bortezomib for relapsed/refractory multiple myeloma – a Nordic comparison.
  Liwing J, GjonnesL, Sandberg I, Renlund M, Aschan J, Lothgren M, Rickert J, Hornberger J, Dhawan R, ISPOR 12th Annual European Congress, Paris, France, 1/1/2009
• A Systematic Literature Review of Utilities Associated With Visual Acuity in Retinal Diseases.
  Hornberger J, Shewade A, Doberne J, Kowalski J, Nguyen H, ARVO Annual Meeting, Ft. Lauderdale, FL, 1/1/2008
• Cost consequences of HIV-associated lipoatrophy.
  Hornberger J, Rajagoapalan R, Shewade A, Loutfy M, Ninth International Congress on Drug Therapy in HIV Infection, (HIV 9), Glasgow, U.K., 1/1/2008
• Cost-effectiveness of Rituximab plus CVP for first-line treatment of advanced indolent lymphoma.
  Hornberger J, Reyes C, Verhulst E, Lubeck D, Valente N, ASCO Annual Meeting, Chicago, IL, 1/1/2007
• Cost-Effectiveness of Rituximab Post CVP Induction for the Treatment of Low-Grade NHL.
  Hornberger J, Reyes C, Shewade A, Loecke D, Valente N, ASH Annual Meeting, Atlanta, GA, 1/1/2007
• 21-gene RT-PCR assay in lymph node negative (LN-), estrogen receptor positive (ER+) breast cancer: An economic analysis including prognostic and predictive information.
  Cosler L, Kuderer N, Hornberger J, Lyman G, ASCO Annual Meeting, Atlanta, GA, 1/1/2006
• Review of economic appraisals of chemotherapy for metastatic colorectal cancer.
  Hornberger J, Robertus K, Bhattacharyya S, Deeter R, ISPOR Eleventh Annual International Meeting, Philadelphia, PA, 1/1/2006
• Cost-utility of stenting for symptomatic intracranial atherosclerotic disease.
  Hornberger J, Robertus K, Deuber N, Reyes C, Hernandez J, Bose A, ISPOR Tenth Annual International Meeting, Washington, DC, 1/1/2005
• Economic analysis of targeting chemotherapy (CT) using a 21 gene RT-PCR assay in lymph node negative (LN-), estrogen receptor positive (ER+) early-stage breast cancer ...
  Cosler L, Hornberger J, Lyman G, ASCO Annual Meeting, New Orleans, LA, 1/1/2004
• Cost-effectiveness of treating adults with chronic hepatitis C (CHC) and persistently normal alanine aminotransferase (PNALT) with peginterferon alfa-2A (40KD) (PEGASY...
  Hornberger J, Farci P, Prati D, Zuezem S, Patel K, Green J, ISPOR Ninth Annual International Meeting, Arlington, VA, 1/1/2004
• Join now to see all

Lectures

• Payment Reform in the United States – A Town-Hall Meeting of the American Society of Clinical Oncology 
  Chicago, IL - 5/31/2014
• The Biggest Threat to Personalized Medicine – Not Paying For Algorithms 
  Silicon Valley, Mountainview, CA - 1/28/2013
• Reimbursement – The Good, the Bad, and the Ugly 
  Boston, MA - 9/4/2012
• An open-source, interactive model to assess the outcomes and economics of diabetes interventions in Canada. 
  Malmo, Sweden - 9/18/2010
• Evaluate and Meet Standards for Generating Credible, Useful Evidence 
  San Diego, CA - 2/22/2010
• How Will Comparative Effectiveness Impact Medical Device Companies? (Panelist) 
  10/12/2009
• Reimbursement and Healthcare Reform 
  Santa Clara University, CA - 6/25/2009
• Pharmacoeconomics, Cost Effectiveness, and Outcome Analysis for Personalized Medicine 
  San Diego, CA - 6/21/2009
• Gaining Coverage and Reimbursement in the Age of Comparative Effectiveness 
  Palo Alto, CA - 6/1/2009
• A Roadmap for Knowing What Works in Health Care: Will a US National Clinical Effectiveness Center or the ARRA’s Comparative Effectiveness Research Program Show the Way... 
  Orlando, FL - 5/16/2009
• A Revised Framework for Appraising Novel Molecular Classifiers (Workshop Presenter) 
  Orlando, FL - 5/16/2009
• Economics of HIV Care (Invited Lecture) 
  Miami, FL - 1/1/2004
• Economic Challenges in Developing Pharmacogenomic Products 
  Tuscon, AZ - 1/1/2001
• Pharmacogenomics in Drug Development 
  Washington, DC - 1/1/2001
• Pharmacogenomics and Ethical Implications of Drug Development 
  Chiron Park, Emeryville, CA - 1/1/2001
• Cost-effectiveness of Rituximab for treatment of patients with large B-cell lymphoma. (Invited Lecture) 
  Harvard University - 1/1/2001
• Herceptin: Targeted Biologic Therapy for Patients with HER2 Protein Overexpressing Metastatic Breast Cancer 
  Tuscon, AZ - 1/1/2001
• Bayesian Analysis: An Introduction 
  Washington, DC - 1/1/1998
• Undertaking cost-beneficial trials in an era of managed care. 
  San Diego, CA - 1/1/1997
• Designing cost-effective clinical studies. 
  Indiana, IN - 1/1/1996
• Consistency of quality-of-life instruments 
  The University of North Carolina, Chapel Hill - 1/1/1995
• Costs of interpreter services. 
  Washington, DC - 1/1/1995
• The economics of addressing patients' concerns. 
  Boston, MA - 1/1/1995
• A novel method for providing interpreter services using remote-simultaneous interpretation. 
  Washington, DC - 1/1/1995
• Technical aspects of guideline development 
  La Jolla, CA - 1/1/1993
• Join now to see all

Other

• National forecasts of ADAP expenditures. 
  Hornberger J, Chun R, MaCurdy T
  1/1/2004
• Fiscal implications of Salt Lake County’s Health Access Project: A Hospital Perspective. 
  Hornberger J, Rapoport D, Marrufo G, HRSA
  10/1/2003
• Master's Thesis: “High-flux dialysis: A technology assessment” 
  Hornberger J, Stanford University
  1/1/1991